Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
Neal D ShoreRaluca Ionescu-IttuLingfeng YangFrançois LalibertéMalena MahendranDominique LejeuneLouise YuJoseph BurgentsMei Sheng DuhSameer R GhatePublished in: Future oncology (London, England) (2021)
Aim: To assess the patterns of genetic testing for homologous recombination repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) pre-PARP inhibitors approval. Patients & methods: mCRPC patients were selected in an oncology electronic medical records database. Patterns and predictors of testing for ATM, BRCA1/2, CDK12, PALB2 and FANCA gene alterations were assessed. Results: Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41). Conclusion: The use of and access to genetic testing pre-PARP inhibitor approval was suboptimal.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- dna damage
- peritoneal dialysis
- healthcare
- gene expression
- palliative care
- dna repair
- squamous cell carcinoma
- dna methylation
- copy number
- genome wide
- pain management
- transcription factor
- cell proliferation
- quality improvement
- chronic pain
- drug induced